Tag Archives: Affordable Care Act

Affordable Care Act: Where's the Sunshine?

Where’s the Sunshine? The Senate Special Committee on Aging is holding a Roundtable discussion on Wed. Sept. 12, 2012 in hopes of spurring action to implement the “Sunshine” provisions of the Affordable Care Act (ACA). Policies for collecting and submitting information on pharma payments to doctors were supposed to be issued by last September (2011), […]
Posted in Guest Blog, healthcare, Op-Ed, Regulatory | Also tagged , , , | Leave a comment

Drug Reimbursement and the "New Medicaid"

by Tom Norton A lot has been written about the “state option” created by the Supreme Court ruling on HCR, and what it means to American medicine. Sorting out an opinion will, to a degree, depend on whom you read and what you believe. But regardless of where you come out on this issue, there […]
Posted in Guest Blog, healthcare, Legal, Market Access, R&D, Regulatory | Also tagged , , , , , , , | 1 Comment

Health Reform Declared Constitutional

It’s back to business for pharma and biotech companies. The main result of the Supreme Court decision upholding the Affordable Care Act (ACA) is that it ends all the rampant speculation and uncertainty about the future shape of the U.S. healthcare system. Now healthcare providers, insurers, medical products makers, and government agencies can move forward […]
Posted in Strategy | Also tagged | Leave a comment

Less is More: HHS Austerity Care

By Tom Norton As the US Department of Health and Human Services (HHS) circles around the elements of health care that will actually be included in our new “Essential Health Benefits” (EHB), one aspect of the EHB offering has caused a tremendous stir among dozens of health groups.  Their collective concern is focused on the […]
Posted in compliance, Guest Blog, healthcare, Legal, Regulatory | Also tagged , , , , , , , | Leave a comment

How Will Accountable Care Organizations Hit Drug Sales?

It’s not yet clear whether physicians will rush to form accountable care organizations (ACOs) in light of newly proposed Centers for Medicare and Medicaid Services (CMS) guidelines, which are lengthy, but pharmaceutical companies hoping to do business with ACOs will have to show that expensive brand drugs can offer not just better health outcomes, but […]
Posted in healthcare, Legal, News, Regulatory, Sales, Strategy | Also tagged , , , , | Leave a comment
  • Categories

  • Meta